2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Lymphoma
3
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Vomiting
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Nausea and Vomiting
1
Philadelphia Chromosome
1
Neuroendocrine Tumors
1
Neoplastic Cells, Circulating
1
Nausea
1
Metastatic Neuroendocrine Prostate Cancer
1
Medulloblastoma
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, B-Cell
1
Leukemia
1
Hematologic Neoplasms
1
Ependymoma
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Bulbo-Spinal Atrophy, X-Linked
1
Advanced Solid Tumors
1
Interventions
Injections
27
Carboplatin
18
Docetaxel
14
pembrolizumab
13
Paclitaxel
12
Bevacizumab
10
durvalumab
8
Nivolumab
8
Cisplatin
8
Fluorouracil
7
Pemetrexed
6
Oxaliplatin
6
Leucovorin
6
trifluridine tipiracil drug combination
5
toripalimab
5
tislelizumab
5
linifanib
5
Capecitabine
5
zimberelimab
4
talazoparib
4
olaparib
4
fludarabine
4
Panobinostat
4
Itraconazole
4
Irinotecan
4
Gemcitabine
4
Everolimus
4
tremelimumab
3
sotorasib
3
sintilimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumors
×
Antiemetics
×
Clear all
NCT06242691
2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2
Completed
13 enrolled
21 charts